NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

What do you think was the placebo in the -L trial?

According to the clinical trial site, the placebo for L are autologous PBMC.

The placebo for ICT-107 was unpulsed autologous DC.

A PBMC is a "peripheral blood mononuclear cell.

Wiki:
A peripheral blood mononuclear cell (PBMC) is any peripheral blood cell having a round nucleus.[1] These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes, whereas erythrocytes and platelets have no nuclei, and granulocytes (neutrophils, basophils, and eosinophils) have multi-lobed nuclei. In humans, lymphocytes make up the majority of the PBMC population, followed by monocytes, and only a small percentage of dendritic cells.

I believe that dendritic cells can be generated from PBMCs, however, I'm thinking that actual dendritic cells, which is what the ICT-107 placebo was comprised of, are actually dendritic cells, whereas the PBMCs are not. So I'm thinking their maturity level is higher, and their ability to favorably impact the immune system would be higher.

But I'm certainly not a scientist, so I could very well be wrong.

I had thought that in the P2 IMUC ICT-107 trial, the control arm had performed, for the most part, very close to what the treatment arm had shown, and some had thought it might have been due to the fact that the control arm has used those autologous unpulsed dendritic cells from the patients themselves. According, too, to the ICT-107 P3 trial, the control had been changed to read simply "placebo." That would indicate some sort of th chase, but I can't easily source what the placebo might have become, and if it were related to the results of the P2 trial.